Skip to main content
. Author manuscript; available in PMC: 2021 Feb 14.
Published in final edited form as: Neuropharmacology. 2019 Oct 22;162:107827. doi: 10.1016/j.neuropharm.2019.107827

Figure 5.

Figure 5.

AQmabAM protection against antibody-dependent cellular cytotoxicity (ADCC) produced by NMO patient sera and NK cells. A. ADCC induced by 1 h incubation of 1–2% NMO serum and NK cells as effector cells, with AQmabAM added prior to serum and NK cells. Cytotoxicity was measured using Alamar blue. B. AQmabAM concentration-dependent protection against cytotoxicity as in A (mean ± S.E.M., n=4) using NMO sera four different patients. C. IC50 for protection against ADCC by AQmab and AQmabAM with each point representing a different human NMO serum (mean ± S.E.M., n=4). D. Live/dead cell assay as done in B, with live cells stained green and dead cells stained red.